# Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC

Source: https://onco.cc/trials/nct07492342/  
OnCo record `nct07492342` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of fulzerasib in lung cancer, run by Jianxing He, now recruiting.

## Summary

Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC is a phase 2, interventional study registered as NCT07492342 by Jianxing He, with a registry enrolment figure of 30 participants, started 2026-01-29 and due to reach its primary completion in 2027-03-31. Interventions recorded: fulzerasib. Conditions listed: Resectable NSCLC; KRAS G12C Mutation; Stage IB-IIIA NSCLC; Neoadjuvant Therapy. Primary outcome: Pathological Complete Response, pCR. Lung eligibility wording from the registry: "Histologically or cytologically confirmed primary non-small cell lung cancer (NSCLC)". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: K-NADIR
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07492342
- Phase: 2
- Setting: Evaluation of Efficacy and Safety of Fulzerasib Sequentially Combined With Sintilimab Plus Platinum-Doublet Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-Small Cell Lung Cancer With KRAS G12 Mutation: a Single-Arm, Phase II Clinical Trial
- Sponsor: Jianxing He
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT07492342: https://clinicaltrials.gov/study/NCT07492342

## Connected records

- cancers: [KRAS G12C-mutant non-small-cell lung cancer](https://onco.cc/cancers/kras-g12c-nsclc/), [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- technologies: [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/)
- drugs: [Fulzerasib](https://onco.cc/drugs/fulzerasib/)
- companies: [Innovent Biologics](https://onco.cc/companies/innovent/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07492342.json